Document is current
Any future updates will be listed below
-
Authors
Kundrod, Kathryn A.
Natoli, Mary E.
Smith, Chelsey A.
Coole, Jackson B.
Chang, Megan M.
Novak, Emilie Newsham
Chiao, Elizabeth
Stier, Elizabeth A.
Montealegre, Jane R.
Scheurer, Michael E.
Castle, Philip E.
Schmeler, Kathleen M.
Richards-Kortum, Rebecca R.
-
Funding
Funding for this research was provided by:
National Cancer Institute (NIH Award R21CA249367)
Cancer Prevention Fellowship Program
MD Anderson Multidisciplinary Research Program
Prevent Cancer Foundation
National Academy of Sciences, United States Agency for International Development (Cooperative Agreement AID-OAA-A-11- 00012)
National Institutes of Health (NIH) through MD Anderson’s Cancer Center Support Grant (P30CA016672)
National Science Foundation Graduate Research Fellowship Program
- License Information
-
More Information
Article History
Received: 7 November 2024
Revised: 2 January 2025
Accepted: 8 January 2025
First Online: 7 February 2025
Declarations
:
: Pre-existing and de-identified cervicovaginal swab samples were provided by the AIDS Malignancy Consortium (AMC).
: PEC has received HPV tests and assays for research at a reduced or no cost from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. MEN is currently an employee of Orasure Technologies, Inc. (formerly Sherlock Biosciences). JRM has received HPV tests for research at no cost from Becton Dickinson. All other authors have no competing interests to declare.
: Sections of this manuscript were previously published in KAK’s doctoral dissertation [].
